Cypherpunk Technologies Inc. (CYPH)
CYPHNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$2.03
-0.1050 (-4.93%) today
Regular session, Nov 11, 3:08 PM ET
- Market cap
- $218.22m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- $1.87 to $2.15
- 52-week range
- $0.4134 to $4.19
- Average volume
- 15.82m
- Previous close
- $2.13
Analysts
1 coveringStrong Buy1 buy, 0 hold, 0 sell
Targets a year out average $4.90, +142.0% from here
Earnings
Next report
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$3.17m | -$5.10m | -$4.82m | -$4.69m |
| Net income | -$3.30m | $40.20m | -$77.17m | $39.39m |
News
8 latest- 2 Cryptocurrencies Poised to Surge 100% in the Coming Years That Savvy Investors Are Already BuyingThe Motley Fool · Oct 10, 2026
- 2 Cryptocurrencies Worth Buying Over AI Stocks Right NowThe Motley Fool · Sep 21, 2026
- Cypherpunk Technologies Consensus Price Target Increased by 206.25% to $5.00Fintel · Sep 15, 2026
- Cypherpunk Swings To Q2 Profit On Zcash Treasury Gains; Advances Phase 3 Sirexatamab Plans;Stock Up RTTNews · Sep 4, 2026
- Biotech Gainers: BTAI Asset Deal, BIAF CyPath Growth, CYPH Zcash, GRI Pipeline Drive Gains RTTNews · Sep 3, 2026
- Leap Therapeutics Slashes R&D SpendingThe Motley Fool · Aug 14, 2025
- Leap Therapeutics Initiates Process To Explore Strategic Options RTTNews · Jun 23, 2025
- Leap Therapeutics, Inc. (LPTX) Q1 Loss Beats Estimates RTTNews · May 13, 2025
The company
Cypherpunk Technologies is a privacy technology company. The Company's mission is to advance technologies that guarantee privacy for humans on the internet. Cypherpunk pursues this mission through three primary strategies: mining Zcash through Cypherpunk Mining; accumulating Zcash through open market purchases; and investing in, acquiring, and building technologies that push the frontier of privacy forward. Additionally, through its subsidiary Leap Therapeutics, the Company is developing novel therapies for patients with cancer by continuing the development of sirexatamab and FL-501.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- cypherpunk.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.